190 related articles for article (PubMed ID: 18581119)
1. Serotonin used as prognostic marker of urological tumors.
Jungwirth N; Haeberle L; Schrott KM; Wullich B; Krause FS
World J Urol; 2008 Oct; 26(5):499-504. PubMed ID: 18581119
[TBL] [Abstract][Full Text] [Related]
2. Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
Alevizopoulos A; Tyritzis S; Leotsakos I; Anastasopoulou I; Pournaras C; Kotsis P; Katsarou O; Alamanis C; Stravodimos K; Constantinides C
Int J Urol; 2017 Feb; 24(2):130-136. PubMed ID: 28004432
[TBL] [Abstract][Full Text] [Related]
3. Serum granulocyte colony-stimulating factor levels in patients with urinary bladder tumour and various urological malignancies.
Mizutani Y; Okada Y; Terachi T; Kakehi Y; Yoshida O
Br J Urol; 1995 Nov; 76(5):580-6. PubMed ID: 8535676
[TBL] [Abstract][Full Text] [Related]
4. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
5. Serum level of immunosuppressive acidic protein in patients with urological malignancies.
Pu YS; Tsai TC; Chiu TY; Hsieh TS; Chen J; Chen SC; Lin MC; Hsu TC
J Formos Med Assoc; 1991 May; 90(5):498-503. PubMed ID: 1680990
[TBL] [Abstract][Full Text] [Related]
6. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies].
Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S
Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396
[TBL] [Abstract][Full Text] [Related]
7. [Significance of current bio- and molecular-markers in urological cancers].
Shimazui T; Akaza H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
[TBL] [Abstract][Full Text] [Related]
8. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
9. Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
Tonyali S; Yazici S
Int Urol Nephrol; 2016 May; 48(5):671-80. PubMed ID: 26843415
[TBL] [Abstract][Full Text] [Related]
10. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
11. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
12. The value of urinary neopterin as an immunological parameter in patients with malignant tumors of the genitourinary tract.
Frick J; Aulitzky W; Fuchs D; Hausen A; Joos H; Reibnegger G; Wachter H
Urol Int; 1985; 40(3):155-9. PubMed ID: 3874460
[TBL] [Abstract][Full Text] [Related]
13. Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
Aveta A; Cilio S; Contieri R; Spena G; Napolitano L; Manfredi C; Franco A; Crocerossa F; Cerrato C; Ferro M; Del Giudice F; Verze P; Lasorsa F; Salonia A; Nair R; Walz J; Lucarelli G; Pandolfo SD
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446024
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein in urologic cancers.
Huang J; Baum Y; Alemozaffar M; Ogan K; Harris W; Kucuk O; Master VA
Mol Aspects Med; 2015 Nov; 45():28-36. PubMed ID: 25936279
[TBL] [Abstract][Full Text] [Related]
15. Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma.
Traeger L; Ellermann I; Wiethoff H; Ihbe J; Gallitz I; Eveslage M; Moritz R; Herrmann E; Schrader AJ; Steinbicker AU
BMC Cancer; 2019 Jan; 19(1):74. PubMed ID: 30646851
[TBL] [Abstract][Full Text] [Related]
16. Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases.
Nazeer T; Ro JY; Amato RJ; Park YW; Ordonez NG; Ayala AG
Oncol Rep; 1998; 5(6):1425-9. PubMed ID: 9769381
[TBL] [Abstract][Full Text] [Related]
17. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer.
Lu JJ; Kakehi Y; Takahashi T; Wu XX; Yuasa T; Yoshiki T; Okada Y; Terachi T; Ogawa O
Clin Cancer Res; 2000 Aug; 6(8):3166-71. PubMed ID: 10955799
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma.
Takashi M; Haimoto H; Tanaka J; Murase T; Kato K
J Urol; 1989 Apr; 141(4):830-4. PubMed ID: 2648028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
